文献速递关节外科

慢性抗生素抑制治疗假体周围感染成功的预测因素

Predictors of Success With Chronic Antibiotic Suppression for Prosthetic Joint Infections.
PubMed 文献 · J Arthroplasty · 2022-02-08

该回顾性队列研究纳入45例培养证实的假体周围感染(PJI)患者,均接受慢性抗生素抑制(CAS)治疗,中位随访50个月。总体成功率为67%(30/45)。在控制体重指数和病原体革兰染色状态后,全髋关节置换术患者较全膝关节置换术患者需再手术的风险更低(HR 0.18,95%CI 0.01-0.96,P=0.04),革兰阳性感染患者较革兰阴性感染患者需再手术的风险更低(HR 0.22,95%CI 0.05-0.88,P=0.03)。作者认为CAS对于缺乏或拒绝进一步手术选择的PJI患者是合理策略。

要点

  • 45例PJI接受CAS,总体成功率67%(30/45),中位随访50个月。
  • 全髋较全膝再手术风险更低(HR 0.18,95%CI 0.01-0.96,P=0.04)。
  • 革兰阳性较革兰阴性感染再手术风险更低(HR 0.22,95%CI 0.05-0.88,P=0.03)。

核心结论

  • CAS对于缺乏或拒绝进一步手术选择的PJI患者是合理策略。
  • 本队列中大多数髋关节感染和革兰阳性感染经CAS成功避免了再手术。

研究设计与样本

  • 回顾性队列研究,纳入培养证实的PJI并接受慢性抑制性抗生素治疗的患者,共45例PJI(31膝、14髋),中位随访50个月(95%CI 33.61-74.02)。
  • 采用Cox比例风险多因素回归模型评估与患者合并症、手术史、受累关节和感染病原体相关的再手术风险因素。
  • 抑制失败定义为开始CAS后再手术或感染导致死亡。

主要发现

  • CAS管理PJI的总体成功率为67%(30/45)。
  • 控制体重指数和病原体革兰染色状态后,全髋关节置换术患者较全膝关节置换术患者需再手术的风险更低(HR 0.18,95%CI 0.01-0.96,P=0.04)。
  • 革兰阳性感染患者较革兰阴性感染患者需再手术的风险更低(HR 0.22,95%CI 0.05-0.88,P=0.03)。
  • 严重抗生素副作用罕见。
  • 经历多次抗生素方案更改的患者更可能CAS失败。

临床怎么用

  • 作者认为CAS对于缺乏或拒绝进一步手术选择的PJI患者是合理策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of recurrent prosthetic joint infection (PJI) after attempted surgical eradication remains a challenge. Chronic antibiotic suppression (CAS) is regarded as a reasonable treatment option for select patients with persistent infection or multiple comorbidities. The study seeks to compare cohorts who succeed and fail with CAS. METHODS: This retrospective cohort study assesses patients who were treated with CAS for a PJI. Patients were included if they had a culture-proven PJI and received chronic suppressive antibiotics. Failure of suppression was defined as reoperation after initiating CAS or death occurring as result of infection. A Cox proportional hazards multivariate regression model was used to estimate risk of reoperation as a function of risk factors related to patient comorbidities, surgical history, affected joint, and infecting organism. RESULTS: We identified 45 PJIs (31 knees, 14 hips) managed with CAS with a median follow-up of 50 (95% confidence interval [CI] 33.61-74.02) months. The overall success rate of managing PJI with CAS was 67% (30/45). Controlling for body mass index and Gram status of the organism, total hip arthroplasty patients were less likely than total knee arthroplasty patients to require reoperation (hazard ratio 0.18, 95% CI 0.01-0.96, P = .04). Patients with Gram-positive infections were less likely than those with a Gram-negative infections to require reoperation (hazard ratio 0.22, 95% CI 0.05-0.88, P = .03). Severe antibiotic side effects were rare. Patients who experienced multiple changes to their antibiotic regimen were more likely to fail with CAS. CONCLUSION: CAS is a reasonable strategy in patients with PJI who lack or refuse further surgical treatment options. Most hips and Gram-positive infections treated with CAS successfully avoided reoperation in this cohort.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Burr RG, Eikani CK, Adams WH, et al. Predictors of Success With Chronic Antibiotic Suppression for Prosthetic Joint Infections. J Arthroplasty. 2022. PMID: 35143924. doi:10.1016/j.arth.2022.02.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。